Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Synmosa BiopharmaROCO:4114 -1.02%83 Net Current Asset Value is NT$2.65 as of Dec. 2025, which is 100% below its 10-year median of 11.32. GuruFocus rates ROCO:4114 with a GF Score™ of 83/100 and a GF Value™ of NT$33.99 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 609 Drug Manufacturers companies, Synmosa Biopharma ranks worse than 74.88% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Synmosa Biopharma's net current asset value per share for the quarter that ended in Dec. 2025 was NT$2.65.
The historical rank and industry rank for Synmosa Biopharma's Net Current Asset Value or its related term are showing as below:
ROCO:4114'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 11.02 Med: 11.32 Max: 11.32
Current: 11.02
During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of Synmosa Biopharma was 11.32. The lowest was 11.02. And the median was 11.32.
ROCO:4114's Price-to-Net-Current-Asset-Value is ranked worse than 74.88% of 609
companies
in the Drug Manufacturers industry
Industry Median: 5.67
vs ROCO:4114: 11.02
Synmosa Biopharma (ROCO:4114) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Synmosa Biopharma Net Current Asset Value Related Terms
Synmosa Biopharma Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for Synmosa Biopharma's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4114 vs ZTS: Net Current Asset Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Synmosa Biopharma's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Synmosa Biopharma Price-to-Net-Current-Asset-Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Synmosa Biopharma's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Synmosa Biopharma's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of NT$2.65 mean?
Synmosa Biopharma (ROCO:4114) has a Net Current Asset Value of NT$2.65 as of Dec. 2025. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Synmosa Biopharma and its competitors. This is 77% below median its historical median of 11.32. Over the past decade, Synmosa Biopharma's Net Current Asset Value has ranged from 11.02 to 11.32. According to the industry distribution chart, Synmosa Biopharma ranks #456 out of 609 companies in the Drug Manufacturers industry, placing it in the top 74.9%.
Is Synmosa Biopharma's Net Current Asset Value too high?
Synmosa Biopharma's current Net Current Asset Value of NT$2.65 is 77% below median its 10-year median of 11.32. Over the past 10 years, this metric has ranged from a low of 11.02 to a high of 11.32. Based on the distribution chart, Synmosa Biopharma ranks #456 out of 609 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Synmosa Biopharma has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Synmosa Biopharma's Net Current Asset Value compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Synmosa Biopharma ranks #456 out of 609 companies for Net Current Asset Value. This places Synmosa Biopharma in the lower half of its industry. The industry median Net Current Asset Value is 5.67. Historically, Synmosa Biopharma's own Net Current Asset Value has ranged from 11.02 to 11.32 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Drug Manufacturers company?
The median Net Current Asset Value among Drug Manufacturers companies is 5.67, based on 609 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Synmosa Biopharma and its competitors. For the Drug Manufacturers industry, the median Net Current Asset Value is 5.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Synmosa Biopharma's current Net Current Asset Value is NT$2.65, which is 77% below median its own 10-year median of 11.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Synmosa Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Synmosa Biopharma (ROCO:4114) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$33.99, compared to a current price of NT$29.20 — trading 14.1% below its estimated fair value. The current Net Current Asset Value is NT$2.65, which is 77% below median its 10-year median of 11.32. Synmosa Biopharma's overall GF Score™ is 83/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Synmosa Biopharma (ROCO:4114), the current Net Current Asset Value is NT$2.65 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Synmosa Biopharma (ROCO:4114) Overvalued in 2026?
Based on GuruFocus' analysis, Synmosa Biopharma stock appears to be undervalued.
The current stock price of NT$29.20 is trading 14.1% below its estimated GF Value™ of NT$33.99.
GuruFocus considers Synmosa Biopharma to be Modestly Undervalued.
Key valuation signals for ROCO:4114:
Net Current Asset Value: NT$2.65 (77% below median its 10-year median of 11.32)
GF Value™: NT$33.99 vs. price of NT$29.20 (14.1% below fair value)
No single metric tells the full story. See the ROCO:4114 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Synmosa Biopharma Corp is engaged in pharmaceuticals and medical devices, cosmetics, animal drugs, chemical food additives, beverages manufacturing and sales, and environmental drugs wholesale (retail), as well as the import and export of related businesses. Its segments include the Active Pharmaceutical Ingredients segment and the Generic Drugs segment. The Generic Drugs segment derives the majority of the revenue.
83GF Score
Get the complete analysis for ROCO:4114
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4114 has been successfully added to your 
